HONG KONG, June 25, 2026 – Regent Pacific Group Limited’s AI-powered biological ageing platform, Deep Longevity, has been awarded second place in the Nestlé VITAL Smart Aging Global Challenge, strengthening its position in the fast-growing longevity technology and preventive healthcare market.
The global innovation competition attracted entries from 150 companies worldwide and was designed to identify technologies that can make healthy ageing more measurable, personalised and accessible for consumers. The recognition places Deep Longevity among the emerging health technology innovators seeking to redefine how individuals, healthcare providers and consumer health brands understand ageing.
Deep Longevity operates at the intersection of artificial intelligence, biological ageing science and personalised health intelligence. Its platform uses AI-powered ageing clocks to assess biological age across multiple physiological and cognitive dimensions, enabling users and healthcare organisations to track health more objectively than through lifestyle questionnaires or self-reported data alone.
The company is part of Regent Pacific Group Limited, a Hong Kong-based diversified investment group focused on healthcare, wellness and life sciences.
The Nestlé VITAL Smart Aging Global Challenge supports Nestlé VITAL, the company’s flagship healthy longevity product line, which is expanding across Latin America, Europe and Asia. The challenge reflects the growing interest among consumer health companies in science-backed tools that can help people understand whether they are ageing well and what interventions may improve their long-term health outcomes.
Making Healthy Ageing Measurable
The healthy ageing market is increasingly shifting from general wellness advice towards measurable, data-driven and personalised interventions. Deep Longevity’s technology is designed to help consumers and healthcare organisations answer a central question: whether an individual is getting healthier or biologically ageing faster than expected.
“This recognition from Nestlé is not just an award, it’s confirmation that the future of consumer health is personalised and measurable,” said Deepankar Nayak, CEO of Deep Longevity. “We built Deep Longevity to answer the question everyone asks as they age: am I getting healthier? Now, for the first time, they can know.”
The company’s platform provides real-time biological age assessment capabilities, allowing users to gain insight into health status and take proactive steps towards improvement.
Its proprietary ageing clocks can be integrated into consumer health products, longevity clinics, diagnostic laboratories, hospitals, insurers and pharmaceutical platforms. This enables organisations to add biological age intelligence directly into their services and product ecosystems.
The recognition by Nestlé is significant because it connects Deep Longevity’s technology with a broader consumer health movement focused on evidence-based healthy ageing.
Nestlé VITAL’s “Intelligent Aging” initiative is built around the idea that ageing well should be grounded in measurable evidence rather than guesswork. Deep Longevity’s platform supports that shift by replacing self-reported habits and supplement tracking with objective biological indicators.
AI and Longevity Science Converge
Deep Longevity’s approach is based on the use of artificial intelligence models trained on large-scale health data. The platform’s validated biological ageing clocks monitor multiple organ systems using metabolic, immunological and physiological markers. These tools are intended to provide a more detailed picture of ageing than chronological age alone.
The company said its AI models have been validated through peer-reviewed research published in international journals, including Aging & Disease.
The technology can be delivered through application programming interfaces and software-as-a-service tools, making it suitable for integration into existing consumer health platforms, clinical workflows and product ecosystems.
This model is important because longevity technology is increasingly moving beyond specialist clinics into mainstream healthcare, diagnostics, insurance, nutrition and wellness services.
Consumer health companies are seeking ways to offer more personalised and measurable interventions, while healthcare providers are exploring preventive models that can identify risks earlier and support more targeted health management.
Deep Longevity’s platform is designed to support personalised health intelligence by moving beyond one-size-fits-all nutrition and wellness recommendations. Instead, it enables interventions based on biological age, organ system markers, cognitive insights and individual health profiles.
The company has also developed AI-powered Mind Age technology, which provides validated cognitive and wellbeing insights across psychological dimensions. This expands its offering beyond physical ageing into mental and cognitive health, supporting a more holistic view of healthy ageing.
Global Expansion Through Healthcare Partnerships
Deep Longevity has been expanding its global reach through partnerships across healthcare and longevity markets. The company has been actively expanding into the United States since earlier this year and has also worked with organisations across Asia, Europe and other regions.
Its partners include Humansa Health, headquartered in Hong Kong and described as Asia’s leading longevity centre; Referans Group, one of Azerbaijan’s largest healthcare and diagnostic networks; Chularat Hospital in Thailand; and Longevitydoc in Europe.
These collaborations reflect the increasing commercialisation of AI-driven longevity science across clinical, diagnostic and consumer health settings.
For healthcare providers, biological age assessment can support preventive care and patient engagement. For consumer health brands, it can create a more evidence-based way to personalise nutrition, supplements and lifestyle interventions. For insurers and pharmaceutical companies, biological ageing data may provide new ways to assess health risk, treatment response and long-term wellbeing.
The recognition from Nestlé could therefore provide Deep Longevity with an important platform for further international expansion, particularly as major food, nutrition and wellness companies invest more heavily in the longevity economy.
Longevity Economy Gains Momentum
The global interest in smart ageing reflects a wider shift in healthcare economics. Chronic diseases account for 90 per cent of the annual US$4.5 trillion healthcare expenditure in the United States, underscoring the financial burden associated with late-stage disease management.
This is helping drive investment into preventive health, early detection, personalised wellness and biological age tracking. The longevity economy is increasingly viewed as a convergence point for artificial intelligence, biotechnology, diagnostics, consumer health, nutrition, digital health platforms and clinical services.
Rather than treating ageing only as a demographic challenge, companies and investors are beginning to approach it as a major opportunity for innovation.
Deep Longevity’s recognition in the Nestlé VITAL Smart Aging Global Challenge highlights this shift. The award suggests that large global consumer health companies are looking for tools that can make ageing visible, measurable and actionable for mainstream users.
For Regent Pacific, the recognition also reinforces its focus on healthcare, wellness and life sciences. The Group has been building a portfolio of corporate and strategic investments in these areas. It has also recently announced that China’s National Medical Products Administration has approved the New Drug Application for Senstend, an innovative treatment for premature ejaculation, inclusive of a four-year data protection period effective from 10 June 2026.
Regent Pacific has returned approximately US$298 million to shareholders since its initial public offering in May 1997.
From Wellness Claims to Evidence-Based Ageing
A key implication of the Nestlé challenge is that the consumer health industry is moving towards greater scientific validation. The wellness market has often been criticised for broad claims and limited measurement. Biological ageing platforms such as Deep Longevity seek to address this gap by providing data-backed indicators that can show whether health interventions are producing measurable effects.
This could change how consumers evaluate supplements, nutrition plans, lifestyle programmes, diagnostics and longevity services. If biological age measurement becomes more widely integrated into consumer health platforms, users may increasingly expect personalised feedback loops rather than generic advice.
For health brands, this creates both an opportunity and a challenge. Companies will need to demonstrate that their products and services are linked to measurable improvements, not just broad wellness positioning. Deep Longevity’s platform is designed to operate within this emerging model by enabling biological and cognitive ageing assessment across multiple systems.
As global populations age and healthcare costs rise, technologies that can support prevention, personalisation and early intervention are likely to attract growing attention. Deep Longevity’s second-place finish in the Nestlé VITAL Smart Aging Global Challenge positions the company within that global conversation, and signals the increasing role of AI-powered biological ageing intelligence in the future of consumer health.